Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Tolterodine tartrate

CAS No.

124937-52-6

Innovator/marketer

Detrusitol

Polymorphic form

Form 1

Therapeutic Area

Genito-urinary system & sex hormones

Status

Commercial

EU DMF readiness

US DMF readiness

024345

CEP

Drug description:

Tolterodine tartrate is a diphenylmethane derivative, acts as an anticholinergic agent.
It is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
It is formulated as film coated tablets for oral route of administration.

Mechanism of action:

Tolterodine is a competitive, specific muscarinic receptor antagonist with a selectivity for the urinary bladder over salivary glands in vivo. One of the tolterodine metabolites (5-hydroxymethyl derivative) exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolizers this metabolite contributes significantly to the therapeutic effect.

DISCLAIMER
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK